Members Obtain Free CE Credits from JCP Articles!

A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1

January 2025 – *The Journal of Clinical Pharmacology* (JCP)

Why is this article important to you?
This activity will expand learner knowledge related to pediatric HIV management, specifically in understanding pharmacokinetics, effective dosing strategies and the application of evidence-based practices to improve treatment adherence and patient outcomes in children living with HIV-1. Learners that complete this activity will recognize the utility of a model-informed drug development approach for Abacavir/Dolutegravir/Lamivudine dosing in pediatric HIV management.

ACPE Accreditation Statement
The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
UAN: 0665-0000-25-001-H01-P – ACPE 1 Contact Hours
Activity Type: Knowledge-based **Format:** Home-study **Target Audience**: 'P'

ACCME Accreditation Statement
The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement
The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
Interprofessional team of Physicians, Pharmacists, PhDs, Pediatricians and Nurses interested in expanding their knowledge on pediatric HIV management utilizing a model-informed drug development approach for Abacavir/Dolutegravir/Lamivudine.

Learning Objectives
After completing this activity, the learner will be able to:

1. Analyze the pharmacokinetic profiles of Abacavir, Dolutegravir and Lamivudine in pediatric populations;
2. Evaluate the impact of model-informed drug development on optimizing dosing regimens for children living with HIV-1;
3. Interpret safety and efficacy data from clinical trials supporting the use of Abacavir/Dolutegravir/Lamivudine in pediatric patients weighing ≥10 kg;
4. Discuss regulatory considerations and bridging strategies that facilitate timely access to effective antiretroviral therapies for children.

Requirements to Receive Credit
In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection:	John van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.
Planner:	Mirshad PV, PhD, Professor, KMCT Medical Coll, planned the continuing education documentation for this course and has nothing to disclose.
CE Reviewer:	Steven Crosby, MA, BSP, RPh, FASCP, FCP, Associate Dean, Associate Professor, Massachusetts Coll of Pharmacy & Health Sciences served as the CE Reviewer and has nothing to disclose.

Schedule & Fees
JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and $75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support
No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates
Date of Issuance: 1/1/2025
Expiration Date: 1/1/2028

Online Location:
https://accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14